Biorestorative Therapies (NASDAQ:BRTX) Announces Earnings Results, Hits Expectations

Biorestorative Therapies (NASDAQ:BRTX) released its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37), Zacks reports. Biorestorative Therapies had a negative return on equity of 231.08% and a negative net margin of 3,308.09%.The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.15 million.

Biorestorative Therapies Price Performance

Shares of Biorestorative Therapies stock traded down $0.01 on Friday, hitting $0.29. 1,031,306 shares of the company’s stock traded hands, compared to its average volume of 9,435,404. The firm’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $1.07. The stock has a market capitalization of $2.58 million, a PE ratio of -0.19 and a beta of 0.47. Biorestorative Therapies has a one year low of $0.19 and a one year high of $2.05.

Institutional Investors Weigh In On Biorestorative Therapies

A number of institutional investors have recently made changes to their positions in BRTX. Citadel Advisors LLC bought a new stake in Biorestorative Therapies in the third quarter valued at about $152,000. DRW Securities LLC bought a new position in Biorestorative Therapies during the fourth quarter worth about $55,000. Finally, Virtu Financial LLC grew its position in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the period. 69.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.